Geographic atrophy

Last updated

Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of visual function over time. [1] [2] [3] [4] It is estimated that GA affects over 5 million people worldwide and approximately 1 million patients in the US, [5] [6] which is similar to the prevalence of neovascular (wet) AMD, the other advanced form of the disease.

Contents

The incidence of advanced AMD, both geographic atrophy and neovascular AMD, increases exponentially with age. The aim of most current clinical trials is to reduce the progression of GA lesion enlargement. [7]

Presentation

Geographic atrophy is a chronic disease, which leads to visual function loss. This often results in difficulties performing daily tasks such as reading, recognizing faces, and driving, and ultimately has severe consequences on independence. [8] [9] [10]

Initially, patients often have good visual acuity if the GA lesions are not involved in the central macular, or foveal, region of the retina. [7] [11] As such, a standard vision test may underrepresent the visual deficit experienced by patients who report challenges reading, driving or seeing in low light conditions. [12] Reading speed is often initially unaffected due to foveal sparing, but worsens progressively as the area of atrophy enlarges. [13] [14] [15] As the disease progresses, vision-related quality-of-life declines markedly. [16]

While fluorescein angiography and optical coherence tomography are today well established for diagnosing and tracking progression in geographic atrophy more complex diagnostic assessments may be required in the context of clinical trials. [17] In February 2023, the FDA approved Pegcetacoplan for the treatment of people with geographic atrophy secondary to age-related macular degeneration. [18]

Pathogenesis

The pathogenesis of GA is not fully understood yet. It is likely multifactorial and triggered by intrinsic and extrinsic stressors of the poorly regenerative retinal pigment epithelium (RPE), particularly oxidative stress caused by the high metabolic demand of photoreceptors, photo-oxidation, and environmental stressors such as cigarette smoke. Variations in several genes, particularly in the complement system, increase the risk of developing GA. This is an active area of research but the current hypothesis is that with aging, damage caused by these stressors accumulates, which coupled with a genetic predisposition, results in the appearance of drusen and lipofuscin deposits (early and intermediate AMD). These and other products of oxidative stress can trigger inflammation via multiple pathways, particularly the complement cascade, ultimately leading to loss of photoreceptors, RPE, and choriocapillaris, culminating in atrophic lesions that grow over time. [19] [20]

Risk factors for GA progression

A plethora of in vivo risk factors for GA progression have been published and validated. [21]

Recent studies indicate that geographic atrophy may be due to deficiencies in blood flow within the choriocapillaris. [22] [23] [24] These studies used swept-source optical coherence tomography angiography to examine the choriocapillaris. Using imaging algorithms, they then determined which regions of the choriocapillaris had deficient blood flow, thus creating a heat map of the blood supply to the retinal pigment epithelium. They went on to use fundus autofluorescence to image the retinal pigment epithelium over the course of a year, this allowed them to map out the direction and magnitude with the geographic atrophy spread. They then found that regions of the choriocapillaris which had less blood flow were more likely to degenerate and become geographic atrophy. Since the choriocapillaris is the main blood supply of the retinal pigment epithelium, it is leading some to believe that geographic atrophy is primarily an ischemic disease (disease due to decreased blood flow).

It was also shown that non-exudative neovascular membranes, which can recapitulate the choriocapillaris, are associated with a markedly slower GA progression. [25] This further supports the vascular insufficiency hypothesis.

Diagnosis

Diagnosis of geographic atrophy is made by an ophthalmologist in the clinic. Fundus autofluorescence and optical coherence tomography angiography are imaging modalities that can be used in the diagnosis. While fundus autofluorescence is the standard modality for viewing geographic atrophy, optical coherence tomography can offer unique benefits. Optical coherence tomography angiography can help the physician see if there is any subretinal fluid in the eye. [26] This is useful because it could indicate that the patient may be developing wet AMD. Since patients with geographic atrophy are at higher risk for developing advanced wet AMD (neovascular AMD), this could be especially useful in the monitoring of patients with geography atrophy. If signs of neovascular AMD found, the physician can initiate treatment of wet age-related macular degeneration. [27]

Quantification of GA progression

Traditionally, GA progression is quantified in terms of the area of retinal pigment epithelium atrophy. [28] Multiple imaging methods can be applied to quantify this area of retinal pigment epithelium atrophy including short-wavelength (blue) fundus autofluorescence imaging, [29] green fundus autofluorescence imaging, [30] and en face optical coherence tomography imaging. [31]

However, more recent data suggest that photoreceptor degeneration is not limited to the area of retinal pigment epithelium atrophy, but extends beyond this area. These more subtle changes can be quantified by volumetric analyses of optical coherence tomography data. [32] [33]

Treatment

In February 2023, Apellis Pharmaceuticals received the first FDA approval of Pegcetacoplan for the treatment of this condition. [34] Cases should be regularly followed by an ophthalmologist so that if patients develop neovascular AMD, they can be treated for that. [35]

Related Research Articles

<span class="mw-page-title-main">Macular degeneration</span> Medical condition associated with vision loss

Macular degeneration, also known as age-related macular degeneration, is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur.

The Age-Related Eye Disease Study (AREDS) was a clinical trial sponsored by the National Eye Institute that ran from 1992-2001. The study was designed to:

<span class="mw-page-title-main">Bruch's membrane</span>

Bruch's membrane is the innermost layer of the choroid of the eye. It is also called the vitreous lamina or Membrane vitriae, because of its glassy microscopic appearance. It is 2–4 μm thick.

<span class="mw-page-title-main">Cone dystrophy</span> Medical condition

A cone dystrophy is an inherited ocular disorder characterized by the loss of cone cells, the photoreceptors responsible for both central and color vision.

<span class="mw-page-title-main">Drusen</span> Medical condition

Drusen, from the German word for node or geode, are tiny yellow or white accumulations of extracellular material that build up between Bruch's membrane and the retinal pigment epithelium of the eye. The presence of a few small ("hard") drusen is normal with advancing age, and most people over 40 have some hard drusen. However, the presence of larger and more numerous drusen in the macula is a common early sign of age-related macular degeneration (AMD).

Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.

Sattler's layer, named after Hubert Sattler, an Austrian ophthalmologist, is one of five layers of medium-diameter blood vessels of the choroid, and a layer of the eye. It is situated between the Bruch's membrane, choriocapillaris below, and the Haller's layer and suprachoroidea above, respectively. The origin seems to be related to a continuous differentiation throughout the growth of the tissue and even further differentiation during adulthood.

<span class="mw-page-title-main">Presumed ocular histoplasmosis syndrome</span> Medical condition

Presumed ocular histoplasmosis syndrome (POHS) is a syndrome affecting the eye, which is characterized by peripheral atrophic chorioretinal scars, atrophy or scarring adjacent to the optic disc and maculopathy.

<span class="mw-page-title-main">Optic disc drusen</span> Medical condition

Optic disc drusen (ODD) are globules of mucoproteins and mucopolysaccharides that progressively calcify in the optic disc. They are thought to be the remnants of the axonal transport system of degenerated retinal ganglion cells. ODD have also been referred to as congenitally elevated or anomalous discs, pseudopapilledema, pseudoneuritis, buried disc drusen, and disc hyaline bodies.

<span class="mw-page-title-main">Choroidal neovascularization</span> Creation of new blood vessels in the choroid layer of the eye

Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye. Choroidal neovascularization is a common cause of neovascular degenerative maculopathy commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments.

<span class="mw-page-title-main">Maculopathy</span> Term for pathological conditions effecting the macula

A maculopathy is any pathological condition of the macula, an area at the centre of the retina that is associated with highly sensitive, accurate vision.

<span class="mw-page-title-main">Intraocular hemorrhage</span> Medical condition

Intraocular hemorrhage is bleeding inside the eye. Bleeding can occur from any structure of the eye where there is vasculature or blood flow, including the anterior chamber, vitreous cavity, retina, choroid, suprachoroidal space, or optic disc.

<span class="mw-page-title-main">Macular telangiectasia</span> Disease of the retina affecting central vision

Macular telangiectasia is a condition of the retina, the light-sensing tissue at the back of the eye that causes gradual deterioration of central vision, interfering with tasks such as reading and driving.

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy secondary to age-related macular degeneration.

Microperimetry, sometimes called fundus-controlled perimetry, is a type of visual field test which uses one of several technologies to create a "retinal sensitivity map" of the quantity of light perceived in specific parts of the retina in people who have lost the ability to fixate on an object or light source. The main difference with traditional perimetry instruments is that, microperimetry includes a system to image the retina and an eye tracker to compensate eye movements during visual field testing.

Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

<span class="mw-page-title-main">Faricimab</span> Medication for macular degeneration

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection by an ophthalmologist.

Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013. As of December 2020, conbercept is undergoing phase III clinical trials through the U.S. Food and Drug Administration’s PANDA-1 and PANDA-2 development programs.

<span class="mw-page-title-main">Stem cell therapy for macular degeneration</span> Use of stem cells to treat macular degeneration

Stem cell therapy for macular degeneration is the use of stem cells to heal, replace dead or damaged cells of the macula in the retina. Stem cell based therapies using bone marrow stem cells as well as retinal pigment epithelial transplantation are being studied. A number of trials have occurred in humans with encouraging results.

Focal choroidal excavation (FCE) is a concavity in the choroidal layer of the eye that can be detected by optical coherence tomography. The disease is usually unilateral and not associated with any accompanying systemic diseases.

References

  1. ↑ Lindblad, AS; Lloyd, PC; Clemons, TE; Gensler, GR; Ferris FL, 3rd; Klein, ML; Armstrong, JR; Age-Related Eye Disease Study Research, Group. (September 2009). "Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26" (PDF). Archives of Ophthalmology. 127 (9): 1168–74. doi:10.1001/archophthalmol.2009.198. PMC   6500457 . PMID   19752426.
  2. ↑ Sunness, JS (3 November 1999). "The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration". Molecular Vision. 5: 25. PMID   10562649.
  3. ↑ Bonilha, Vera L (2008). "Age and disease-related structural changes in the retinal pigment epithelium". Clinical Ophthalmology. 2 (2): 413–424. doi:10.2147/opth.s2151. ISSN   1177-5467. PMC   2693982 . PMID   19668732.
  4. ↑ Lindner, Moritz; Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Holz, Frank G. (2018), "Atrophy, Geographic", Encyclopedia of Ophthalmology, Springer Berlin Heidelberg, pp. 207–209, doi:10.1007/978-3-540-69000-9_1125, ISBN   9783540682929
  5. ↑ Wong, Wan Ling; Su, Xinyi; Li, Xiang; Cheung, Chui Ming G; Klein, Ronald; Cheng, Ching-Yu; Wong, Tien Yin (February 2014). "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis". The Lancet Global Health. 2 (2): e106–e116. doi: 10.1016/S2214-109X(13)70145-1 . PMID   25104651.
  6. ↑ Rudnicka, Alicja R.; Kapetanakis, Venediktos V.; Jarrar, Zakariya; Wathern, Andrea K.; Wormald, Richard; Fletcher, Astrid E.; Cook, Derek G.; Owen, Christopher G. (July 2015). "Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis". American Journal of Ophthalmology. 160 (1): 85–93.e3. doi: 10.1016/j.ajo.2015.04.003 . PMID   25857680.
  7. 1 2 Sadda, SriniVas R.; Chakravarthy, Usha; Birch, David G.; Staurenghi, Giovanni; Henry, Erin C.; Brittain, Christopher (October 2016). "Clinical Endpoints for the Study of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retina. 36 (10): 1806–1822. doi:10.1097/IAE.0000000000001283. PMC   5384792 . PMID   27652913.
  8. ↑ Brown, Jamie C.; Goldstein, Judith E.; Chan, Tiffany L.; Massof, Robert; Ramulu, Pradeep (August 2014). "Characterizing Functional Complaints in Patients Seeking Outpatient Low-Vision Services in the United States". Ophthalmology. 121 (8): 1655–1662.e1. doi:10.1016/j.ophtha.2014.02.030. PMC   6746569 . PMID   24768243.
  9. ↑ Tschosik, Elizabeth; Leidy, Nancy Kline; Kimel, Miriam; Dolan, Chantal; Souied, Eric; Varma, Rohit; Bressler, Neil M. (11 June 2015). "Quantifying functional reading independence in geographic atrophy: the FRI Index". Investigative Ophthalmology & Visual Science. 56 (7): 4789. ISSN   1552-5783.
  10. ↑ DeCarlo, DK; Scilley, K; Wells, J; Owsley, C (March 2003). "Driving habits and health-related quality of life in patients with age-related maculopathy". Optometry and Vision Science. 80 (3): 207–13. doi:10.1097/00006324-200303000-00010. PMID   12637832. S2CID   11146594.
  11. ↑ Lindner, Moritz; Böker, Alexander; Mauschitz, Matthias M.; Göbel, Arno P.; Fimmers, Rolf; Brinkmann, Christian K.; Schmitz-Valckenberg, Steffen; Schmid, Matthias; Holz, Frank G. (July 2015). "Directional Kinetics of Geographic Atrophy Progression in Age-Related Macular Degeneration with Foveal Sparing". Ophthalmology. 122 (7): 1356–1365. doi:10.1016/j.ophtha.2015.03.027. ISSN   0161-6420. PMID   25972258.
  12. ↑ Sunness, JS; Applegate, CA; Haselwood, D; Rubin, GS (September 1996). "Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease". Ophthalmology. 103 (9): 1458–66. doi:10.1016/S0161-6420(96)30483-1. PMC   2730505 . PMID   8841306.
  13. ↑ Sunness JS, Rubin GS, Zuckerbrod A, Applegate CA (October 2008). "Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration". J Vis Impair Blind. 102 (10): 600–610. doi:10.1177/0145482X0810201004. PMC   2836024 . PMID   20224750.
  14. ↑ Lindner M, Pfau M, Czauderna J, Goerdt L, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2019). "Determinants of Reading Performance in Eyes with Foveal-Sparing Geographic Atrophy". Ophthalmol Retina. 3 (3): 201–210. doi:10.1016/j.oret.2018.11.005. PMID   31014695. S2CID   81733640.
  15. ↑ Künzel SH, Lindner M, Sassen J, Möller PT, Goerdt L, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (September 2021). "Association of Reading Performance in Geographic Atrophy Secondary to Age-Related Macular Degeneration With Visual Function and Structural Biomarkers". JAMA Ophthalmol. 139 (11): 1191–1199. doi:10.1001/jamaophthalmol.2021.3826. PMC   8485212 . PMID   34591067.
  16. ↑ Künzel SH, Möller PT, Lindner M, Goerdt L, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (May 2020). "Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration". Invest Ophthalmol Vis Sci. 61 (5): 63. doi:10.1167/iovs.61.5.63. PMC   7405807 . PMID   32462198.
  17. ↑ Holz, Frank G.; Sadda, SriniVas R.; Staurenghi, Giovanni; Lindner, Moritz; Bird, Alan C.; Blodi, Barbara A.; Bottoni, Ferdinando; Chakravarthy, Usha; Chew, Emily Y. (April 2017). "Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings". Ophthalmology. 124 (4): 464–478. doi: 10.1016/j.ophtha.2016.12.002 . ISSN   1549-4713. PMID   28109563.
  18. ↑ "FDA Approves Syfovre (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness" (Press release). Apellis Pharmaceuticals. 17 February 2023. Archived from the original on 17 February 2023. Retrieved 18 February 2023– via GlobeNewswire.
  19. ↑ Holz, Frank G.; Strauss, Erich C.; Schmitz-Valckenberg, Steffen; van Lookeren Campagne, Menno (May 2014). "Geographic atrophy: clinical features and potential therapeutic approaches". Ophthalmology. 121 (5): 1079–1091. doi:10.1016/j.ophtha.2013.11.023. PMID   24433969.
  20. ↑ Saleh Abdelfattah, Nizar; Zhang, Hongyang; Boyer, David S.; Sadda, SriniVas R. (2016). "Progression of Macular Atrophy in Patients with Neovascular Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy". Retina. 36 (10): 1843–1850. doi:10.1097/iae.0000000000001059. PMID   27135213. S2CID   28757961.
  21. ↑ Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, Henry EC, Ferrara D (March 2018). "The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Ophthalmology. 125 (3): 369–390. doi: 10.1016/j.ophtha.2017.08.038 . PMID   29110945.
  22. ↑ Thulliez, M (June 2019). "Correlations between Choriocapillaris Flow Deficits around Geographic Atrophy and Enlargement Rates Based on Swept-Source OCT Imaging". Ophthalmol Retina. 3 (6): 478–488. doi:10.1016/j.oret.2019.01.024. PMID   31174669. S2CID   86851083.
  23. ↑ Nassisi, M (21 August 2018). "Choriocapillaris impairment around the atrophic lesions in patients with geographic atrophy: a swept-source optical coherence tomography angiography study". Br J Ophthalmol. 103 (7): 911–917. doi: 10.1136/bjophthalmol-2018-312643 . PMID   30131381.
  24. ↑ Müller PL, Pfau M, Möller PT, Nadal J, Schmid M, Lindner M, de Sisternes L, Stöhr H, Weber BH, Neuhaus C, Herrmann P, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2018). "Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related Macular Degeneration: An OCT-Angiography Study". Invest Ophthalmol Vis Sci. 59 (4): AMD122–AMD131. doi: 10.1167/iovs.18-23819 . PMID   30140905. S2CID   52077435.
  25. ↑ Pfau M, Möller PT, Künzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2020). "Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration". Ophthalmol Retina. 4 (3): 238–248. doi:10.1016/j.oret.2019.09.016. PMID   31753808. S2CID   208226972.
  26. ↑ Garcia-Layana, Alfredo. "Optical Coherence Tomography in Age-related Macular Degeneration". AMD book. Retrieved 8 December 2019.
  27. ↑ Malciolu Radu Alexandru (January–March 2016). "Wet age-related macular degeneration management and follow-up". Rom J Ophthalmol. 60 (1): 9–13. PMC   5712923 . PMID   27220225.
  28. ↑ Fleckenstein, M; Mitchell, P; Freund, KB; Sadda, S; Holz, FG; Brittain, C; Henry, EC; Ferrara, D (March 2018). "The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Ophthalmology. 125 (3): 369–390. doi: 10.1016/j.ophtha.2017.08.038 . PMID   29110945.
  29. ↑ Schmitz-Valckenberg S, Brinkmann CK, Alten F, Herrmann P, Stratmann NK, Göbel AP, Fleckenstein M, Diller M, Jaffe GJ, Holz FG (September 2011). "Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration". Invest Ophthalmol Vis Sci. 52 (10): 7640–6. doi:10.1167/iovs.11-7457. PMID   21873669.
  30. ↑ Pfau M, Goerdt L, Schmitz-Valckenberg S, Mauschitz MM, Mishra DK, Holz FG, Lindner M, Fleckenstein M (May 2017). "Green-Light Autofluorescence Versus Combined Blue-Light Autofluorescence and Near-Infrared Reflectance Imaging in Geographic Atrophy Secondary to Age-Related Macular Degeneration". Invest Ophthalmol Vis Sci. 58 (6): BIO121–BIO130. doi: 10.1167/iovs.17-21764 . PMID   28632841. S2CID   10855695.
  31. ↑ Shi Y, Zhang Q, Zhou H, Wang L, Chu Z, Jiang X, Shen M, Thulliez M, Lyu C, Feuer W, de Sisternes L, Durbin MK, Gregori G, Wang RK, Rosenfeld PJ (April 2021). "Correlations Between Choriocapillaris and Choroidal Measurements and the Growth of Geographic Atrophy Using Swept Source OCT Imaging". Am J Ophthalmol. 224: 321–331. doi:10.1016/j.ajo.2020.12.015. PMC   8058170 . PMID   33359715.
  32. ↑ Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Rubin DL (October 2020). "Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration". JAMA Ophthalmol. 138 (10): 1026–1034. doi:10.1001/jamaophthalmol.2020.2914. PMC   7426886 . PMID   32789526.
  33. ↑ Reiter GS, Told R, Schranz M, Baumann L, Mylonas G, Sacu S, Pollreisz A, Schmidt-Erfurth U (June 2020). "Subretinal Drusenoid Deposits and Photoreceptor Loss Detecting Global and Local Progression of Geographic Atrophy by SD-OCT Imaging". Invest Ophthalmol Vis Sci. 61 (6): 11. doi:10.1167/iovs.61.6.11. PMC   7415285 . PMID   32503052.
  34. ↑ FDA Approves First Treatment for Geographic Atrophy
  35. ↑ Lai, K (January 2015). "Current choice of treatments for neovascular AMD". Expert Rev Clin Pharmacol. 8 (1): 135–40. doi:10.1586/17512433.2015.990379. PMID   25487081. S2CID   31943205.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.